The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a myeloproliferative disorder that caused by the formation of fusion onco-protein, BCR-ABL. Since BCR-ABL plays role in progression CML, most common treatments CML are tyrosine kinase inhibitors (TKIs) specifically target However, resistance to TKIs major problem treatment. A promising overcoming drug other cancers thioredoxin (TRX) system, an antioxidant system maintains cellular redox homeostasis. The TRX upregulated many and this associated with poor prognosis. Analysis patient database showed expression was patients compared healthy donors. Our experiments revealed significant link between systems since inhibition chemical siRNA resulted decrease activity cells. This notable as it shows may be viable treatment CML.